Pharmacovigilance, across the lifecycle. for the lifecycle.

The continuity story from Phase 1 through twenty-plus years of postmarket surveillance. Citation-bound attribution, MedDRA coding, ICSR-ready output, and the architectural argument for keeping a single platform across the drug lifecycle.

For PV leadership, MedDRA stewardship, and the postmarket safety bench

• Lifecycle architecture: clinical trial through postmarket surveillance
• Citation-bound attribution under WHO-UMC and Kramer
• MedDRA coding pipeline with active validation
• ICSR-ready output for downstream PV platforms
• The argument for one platform across the drug lifecycle